MX2011012310A - Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). - Google Patents
Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).Info
- Publication number
- MX2011012310A MX2011012310A MX2011012310A MX2011012310A MX2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A MX 2011012310 A MX2011012310 A MX 2011012310A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- heart failure
- ejection fraction
- normal ejection
- hfnef
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 abstract 3
- 229960000989 perhexiline Drugs 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000011260 co-administration Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2009/050539 WO2010133815A1 (en) | 2009-05-20 | 2009-05-20 | Treatment of heart failure with normal ejection fraction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011012310A true MX2011012310A (es) | 2012-04-11 |
Family
ID=41213178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012310A MX2011012310A (es) | 2009-05-20 | 2009-05-20 | Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8440697B2 (https=) |
| EP (1) | EP2432470A1 (https=) |
| JP (1) | JP2012527438A (https=) |
| CN (1) | CN102573844A (https=) |
| AU (1) | AU2009346606B2 (https=) |
| BR (1) | BRPI0924398A2 (https=) |
| CA (1) | CA2816448A1 (https=) |
| IL (1) | IL216362A0 (https=) |
| MX (1) | MX2011012310A (https=) |
| WO (1) | WO2010133815A1 (https=) |
| ZA (1) | ZA201109332B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| CN102573844A (zh) | 2009-05-20 | 2012-07-11 | 心脏麦塔波里卡斯有限公司 | 射血分数正常心力衰竭的治疗 |
| CA2845228C (en) | 2011-08-16 | 2021-08-10 | Baker Idi Heart & Diabetes Institute Holdings Limited | Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds |
| CA2883773A1 (en) * | 2012-09-05 | 2014-03-13 | Adelaide Research & Innovation Pty Ltd. | Uses of (-)-perhexiline |
| JP2018500365A (ja) | 2014-12-22 | 2018-01-11 | カーディオラ ピーティーワイ リミテッド | 治療方法 |
| JP6878589B2 (ja) | 2016-12-15 | 2021-05-26 | バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ | 感知された静脈波形から患者パラメータを監視および決定するためのシステムおよび方法 |
| US11039754B2 (en) | 2018-05-14 | 2021-06-22 | Baxter International Inc. | System and method for monitoring and determining patient parameters from sensed venous waveform |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN380695A0 (en) | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
| US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
| CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
| GB0405381D0 (en) * | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
| EP1737452A1 (en) | 2004-04-06 | 2007-01-03 | Angiogenetics Sweden AB | Angiogenesis-affecting compounds and methods of use thereof |
| EP1959951B1 (en) | 2005-12-01 | 2009-12-23 | F. Hoffmann-la Roche AG | Heteroaryl substituted piperidine derivatives as l-cpt1 inhibitors |
| ITRM20060090A1 (it) | 2006-02-22 | 2007-08-23 | Sigma Tau Ind Farmaceuti | Nuovi composti inibitori cpt a livello del snc come farmaci antidiabetici e o antiobesita |
| GB0723100D0 (en) * | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
| GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
| CN102573844A (zh) | 2009-05-20 | 2012-07-11 | 心脏麦塔波里卡斯有限公司 | 射血分数正常心力衰竭的治疗 |
| US20140019207A1 (en) | 2012-07-11 | 2014-01-16 | Sap Ag | Interactive in-memory based sales forecasting |
| CA2883773A1 (en) | 2012-09-05 | 2014-03-13 | Adelaide Research & Innovation Pty Ltd. | Uses of (-)-perhexiline |
| WO2015131231A1 (en) | 2014-03-03 | 2015-09-11 | Adelaide Research & Innovation Pty Ltd | Methods for using (-)-perhexiline |
-
2009
- 2009-05-20 CN CN2009801606783A patent/CN102573844A/zh active Pending
- 2009-05-20 WO PCT/GB2009/050539 patent/WO2010133815A1/en not_active Ceased
- 2009-05-20 MX MX2011012310A patent/MX2011012310A/es unknown
- 2009-05-20 BR BRPI0924398A patent/BRPI0924398A2/pt not_active IP Right Cessation
- 2009-05-20 JP JP2012511329A patent/JP2012527438A/ja active Pending
- 2009-05-20 EP EP09785222A patent/EP2432470A1/en not_active Withdrawn
- 2009-05-20 AU AU2009346606A patent/AU2009346606B2/en not_active Ceased
- 2009-05-20 CA CA2816448A patent/CA2816448A1/en not_active Abandoned
-
2010
- 2010-05-21 US US12/785,077 patent/US8440697B2/en not_active Expired - Fee Related
-
2011
- 2011-11-14 IL IL216362A patent/IL216362A0/en unknown
- 2011-12-19 ZA ZA2011/09332A patent/ZA201109332B/en unknown
-
2013
- 2013-03-15 US US13/838,458 patent/US9457017B2/en not_active Expired - Fee Related
- 2013-03-15 US US13/839,313 patent/US9468634B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20100331364A1 (en) | 2010-12-30 |
| AU2009346606A1 (en) | 2012-01-19 |
| ZA201109332B (en) | 2012-08-29 |
| US9468634B2 (en) | 2016-10-18 |
| EP2432470A1 (en) | 2012-03-28 |
| AU2009346606B2 (en) | 2016-06-02 |
| CA2816448A1 (en) | 2010-11-25 |
| US9457017B2 (en) | 2016-10-04 |
| WO2010133815A1 (en) | 2010-11-25 |
| BRPI0924398A2 (pt) | 2019-09-24 |
| IL216362A0 (en) | 2012-01-31 |
| US8440697B2 (en) | 2013-05-14 |
| US20130210720A1 (en) | 2013-08-15 |
| JP2012527438A (ja) | 2012-11-08 |
| US20130210719A1 (en) | 2013-08-15 |
| CN102573844A (zh) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012131A (es) | Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm). | |
| MX2011012310A (es) | Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen). | |
| WO2012062925A3 (en) | Compounds and methods for treating pain | |
| PH12013500919B1 (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| WO2009045356A3 (en) | Microrna compositions in the treatment of vegf-mediated disorders | |
| MA32389B1 (fr) | Methode de traitement de la dyspnee associee a une insuffisance cardiaque aigue | |
| WO2010071826A3 (en) | Methods for treating osteoclast-related disease, compounds and compositions thereof | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| UA105029C2 (uk) | ПОДВІЙНЕ НАЦІЛЮВАННЯ НА miR-208 І miR-499 У ЛІКУВАННІ ЗАХВОРЮВАНЬ СЕРЦЯ | |
| MX2010002312A (es) | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. | |
| EA201290859A1 (ru) | Лечение люпус-артрита с использованием лаквинимода | |
| MX2012000034A (es) | Metodos para el tratamiento o la prevencion de la fatiga. | |
| EP2294184A4 (en) | TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY | |
| WO2012020307A3 (en) | Therapeutic uses of microvesicles and related micrornas | |
| MY150602A (en) | Subtituted-quinoxaline-type piperidine compounds and the uses thereof | |
| WO2009137465A3 (en) | Compositions for treatment or prevention of pathological cardiac remodeling and heart failure | |
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| MX350745B (es) | El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| MX348898B (es) | Métodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. | |
| MX367811B (es) | D-metadona para el tratamiento de síntomas psiquiátricos. | |
| MX2013002212A (es) | Tratamiento de hipertension y/o prevencion o tratamiento de insuficiencia cardiaca en un mamifero que recibe terapia anti-coagulante. | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| AR092103A1 (es) | Laquinimod en el tratamiento de los trastornos mediados por el receptor de canabinoides del tipo 1 (cb1) |